Yuval Shaked

Summary

Affiliation: Technion-Israel Institute of Technology
Country: Israel

Publications

  1. ncbi request reprint Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing
    Dror Alishekevitz
    Corresponding Author Yuval Shaked, Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, 1 Efron St Bat Galim, Haifa, Israel 31096
    Mol Cancer Ther 13:202-13. 2014
  2. pmc Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents
    Yuval Shaked
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Cancer Res 69:7524-8. 2009
  3. ncbi request reprint Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?
    Yuval Shaked
    Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Biochim Biophys Acta 1796:1-4. 2009
  4. pmc Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
    Yuval Shaked
    Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
    Cancer Cell 14:263-73. 2008
  5. pmc Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models
    Laura G Daenen
    Molecular and Cell Biology Research, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    Mol Cancer Ther 8:2872-81. 2009
  6. ncbi request reprint Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
    Yuval Shaked
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    Science 313:1785-7. 2006
  7. pmc Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1
    Chris Folkins
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 69:7243-51. 2009
  8. ncbi request reprint Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin
    Ella Fremder
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine and Research Institute, Technion, Haifa, Israel
    Int J Cancer 135:270-81. 2014
  9. ncbi request reprint Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia
    Urban Emmenegger
    Molecular and Cellular Biology Research and Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Cancer Res 66:1664-74. 2006
  10. ncbi request reprint Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy
    Yuval Shaked
    Department of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre and the Department of Medical Biophysics, University of Toronto, Ontario, Canada
    Cancer Res 65:7045-51. 2005

Collaborators

Detail Information

Publications52

  1. ncbi request reprint Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing
    Dror Alishekevitz
    Corresponding Author Yuval Shaked, Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, 1 Efron St Bat Galim, Haifa, Israel 31096
    Mol Cancer Ther 13:202-13. 2014
    ..These results may implicate an additional therapeutic role for anti-VEGF-A when combined with chemotherapy...
  2. pmc Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents
    Yuval Shaked
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Cancer Res 69:7524-8. 2009
    ..These results highlight the possible effect of drug-induced G-CSF on tumor regrowth following certain cytotoxic drug therapies, in this case using a VDA, and hence G-CSF as a possible therapeutic target...
  3. ncbi request reprint Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?
    Yuval Shaked
    Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Biochim Biophys Acta 1796:1-4. 2009
    ..g., VEGF blocking antibodies...
  4. pmc Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
    Yuval Shaked
    Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
    Cancer Cell 14:263-73. 2008
    ....
  5. pmc Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models
    Laura G Daenen
    Molecular and Cell Biology Research, Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada
    Mol Cancer Ther 8:2872-81. 2009
    ..The combination of OXi4503 and metronomic chemotherapy results in prolonged tumor control, thereby expanding the list of therapeutic agents that can be successfully integrated with metronomic low-dose chemotherapy...
  6. ncbi request reprint Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
    Yuval Shaked
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    Science 313:1785-7. 2006
    ..These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs...
  7. pmc Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1
    Chris Folkins
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 69:7243-51. 2009
    ....
  8. ncbi request reprint Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: a process regulated by osteopontin
    Ella Fremder
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine and Research Institute, Technion, Haifa, Israel
    Int J Cancer 135:270-81. 2014
    ..Collectively, our results suggest that osteopontin expressed by TMPs play an important role in BMDC mobilization and colonization of tumors, but is not sufficient to enhance the angiogenic activity in tumors. ..
  9. ncbi request reprint Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia
    Urban Emmenegger
    Molecular and Cellular Biology Research and Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Cancer Res 66:1664-74. 2006
    ..These results provide further evidence that reduced vascular dependence/increased hypoxia tolerance may be a basis for eventual resistance of tumors exposed to long-term LDM chemotherapy...
  10. ncbi request reprint Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy
    Yuval Shaked
    Department of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre and the Department of Medical Biophysics, University of Toronto, Ontario, Canada
    Cancer Res 65:7045-51. 2005
    ....
  11. ncbi request reprint Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors
    Chris Folkins
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario, Canada
    Cancer Res 67:3560-4. 2007
    ....
  12. pmc G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist
    Tali Voloshin
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Blood 118:3426-35. 2011
    ....
  13. pmc Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia
    David Cervi
    Department of Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada
    Blood 109:2139-46. 2007
    ..We propose that a compensatory erythropoietic response combined with increased natural killer (NK) cell activity account for the extended survival of erythroleukemic, Vegfhi/+ mice...
  14. pmc Porfimer-sodium (Photofrin-II) in combination with ionizing radiation inhibits tumor-initiating cell proliferation and improves glioblastoma treatment efficacy
    Liat Benayoun
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Cancer Biol Ther 14:64-74. 2013
    ....
  15. doi request reprint Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines
    Giulio Francia
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Mol Cancer Ther 7:3452-9. 2008
    ..Collectively, our data indicates that beta-hCG is an effective noninvasive preclinical marker for the long term monitoring of untreated or treated metastatic disease...
  16. ncbi request reprint Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose
    Yuval Shaked
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Curr Cancer Drug Targets 5:551-9. 2005
    ..Finally, another promising marker we discuss is soluble VEGFR-2...
  17. ncbi request reprint Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs
    Liat Benayoun
    Department of Molecular Pharmacology, Technion, Haifa, Israel
    Stem Cells 30:1831-41. 2012
    ..Collectively, our results suggest that the efficacy of antiangiogenic drugs is dependent on the angiogenic properties of TICs and, therefore, can serve as a possible biomarker to predict antiangiogenic treatment efficacy...
  18. pmc Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide
    Urban Emmenegger
    Molecular and Cellular Biology Research, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
    Neoplasia 13:40-8. 2011
    ..As such, our findings have various implications for the clinical use of metronomic chemotherapy...
  19. ncbi request reprint Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice
    Urban Emmenegger
    Division of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Mol Cancer Ther 6:2280-9. 2007
    ..LDM CPA-associated changes of CYP3A4 activity point to a potential risk of unfavorable drug interactions when compounds that are metabolized by CYP3A4 are coadministered with LDM CPA...
  20. doi request reprint Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice
    Svetlana Gingis-Velitski
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Cancer Res 71:6986-96. 2011
    ..Taken together, our findings illustrate how some chemotherapies can exert prometastatic effects that may confound treatment outcomes...
  21. pmc Dissecting the autocrine and paracrine roles of the CCR2-CCL2 axis in tumor survival and angiogenesis
    Liat Izhak
    Department of Immunology, Rappaport Institute for Medical Research, Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
    PLoS ONE 7:e28305. 2012
    ..This further emphasizes the important role of CCL2 as a target for therapy of cancer diseases...
  22. ncbi request reprint Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents
    Giulio Francia
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, University of Toronto, S 217 Research Building, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Mol Cancer Ther 4:1484-94. 2005
    ....
  23. doi request reprint Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer
    Urban Emmenegger
    Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, 2075, Bayview Avenue, Toronto, ON, Canada, M4N3M5
    Recent Results Cancer Res 180:165-83. 2010
    ..Based on preclinical findings, we finally point to the possible ways to address these shortcomings in order to bring this novel and promising use of conventional anticancer agents to full fruition...
  24. pmc Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
    Yuval Shaked
    Sunnybrook and Women s College Health Sciences Centre, Molecular and Cellular Biology Research, Department of Medical Biophysics, University of Toronto, Ontarip, Canada
    Blood 106:3058-61. 2005
    ..These results suggest that CEPs may serve as a pharmacodynamic biomarker to determine the OBD of metronomic chemotherapy regimens...
  25. ncbi request reprint Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel
    Sylvia S W Ng
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    Clin Cancer Res 12:4331-8. 2006
    ..We hypothesized that ABI-007, a cremophor EL-free, albumin-bound, 130-nm form of paclitaxel, could potentially alleviate this problem...
  26. pmc An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice
    Daniel Voskas
    Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    J Leukoc Biol 84:59-67. 2008
    ....
  27. pmc The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells
    Yuval Shaked
    Department of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre, Toronto, ON, Canada
    Blood 105:4500-7. 2005
    ..These findings suggest that VEGF-A and MCP-5 are potentially pivotal paracrine mediators occurring within the diseased splenic microenvironment capable of promoting disease acceleration and expansion of erythroleukemic blasts...
  28. ncbi request reprint Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
    Yuval Shaked
    Department of Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre, Toronto, Ontario M3N 4M5, Canada
    Cancer Cell 7:101-11. 2005
    ..Finally, treatment with a targeted VEGFR-2 antibody caused a dose-dependent reduction in viable CEPs that precisely paralleled its previously and empirically determined antitumor activity...
  29. doi request reprint In vitro enrichment of tumor-initiating cells from human established cell lines
    Liat Benayoun
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
    Curr Protoc Stem Cell Biol . 2013
    ..Studying TICs by using such protocols is cost effective and is considered as a suitable and simple way for studying them...
  30. ncbi request reprint Anti-bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy
    Erez Hasnis
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Haifa, Israel Department of Internal Medicine C, Rambam Health Care Campus, Haifa, Israel
    Neoplasia 16:501-10. 2014
    ..Therefore, both Bv8 inhibition and MC can be used as legitimate 'add-on' treatments for preventing post-chemotherapy pancreatic cancer recurrence, progression, and metastasis following weekly gemcitabine therapy. ..
  31. pmc Anti-VEGF-A affects the angiogenic properties of tumor-derived microparticles
    Michal Munster
    Department of Molecular Pharmacology, Rappaport Faculty of Medicine, Technion, Haifa, Israel
    PLoS ONE 9:e95983. 2014
    ....
  32. doi request reprint Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours
    Shelly Zaffryar-Eilot
    Cancer and Vascular Biology Research Center, Technion Israel Institute of Technology, Haifa 31096, Israel
    Carcinogenesis 34:2370-9. 2013
    ..Indeed, treatment with AB0023 significantly enhanced the anti-tumourigenic effects of taxol. Our results suggest that inhibition of LOXL2 may prove beneficial for the treatment of angiogenic tumours. ..
  33. pmc Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth
    Michael C Schmid
    Moores UCSD Cancer Center, University of California, San Diego, California, USA
    Cancer Res 71:6965-75. 2011
    ..These results show that targeting myeloid cell recruitment mechanisms can be an effective approach to suppress tumor progression...
  34. ncbi request reprint Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy
    Yuval Shaked
    Sunnybrook Health Sciences Centre, Molecular and Cellular Biology Research, and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 67:7055-8. 2007
    ....
  35. ncbi request reprint A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens
    Urban Emmenegger
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada
    Cancer Res 64:3994-4000. 2004
    ..LDM offers clear safety advantages over conventional MTD chemotherapy and therefore would appear to be ideal for long-term combination therapy with targeted antiangiogenic drugs...
  36. ncbi request reprint Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner
    Liat Izhak
    Department of Immunology, The Ruth and Bruce Rappaport Faculty of Medicine, Rappaport Family Institute for Research in the Medical Sciences, Technion Institute of Technology, Haifa, Israel
    J Immunol 184:1092-101. 2010
    ..From a clinically oriented perspective, we show, in an experimental model of the disease, that DNA-based amplification of this response suppresses disease, which has implications for a novel way of therapy in humans...
  37. ncbi request reprint Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase
    Brian J Pak
    Molecular and Cellular Biology, Sunnybrook and Women s College Health Sciences Centre and Toronto Sunnybrook Regional Cancer Centre, University of Toronto, Toronto, Ontario, Canada
    Oncogene 23:30-8. 2004
    ....
  38. ncbi request reprint Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia
    Marcela Franco
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Cancer Res 66:3639-48. 2006
    ..The implications of the results are discussed, particularly with respect to how they relate to different theories for the counterintuitive chemosensitizing effects of antiangiogenic drugs, even when hypoxia is increased...
  39. pmc Id1 restrains p21 expression to control endothelial progenitor cell formation
    Alessia Ciarrocchi
    Program of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America
    PLoS ONE 2:e1338. 2007
    ..These results demonstrate that the restraint of p21 expression by Id1 is one key element of its activity in facilitating the generation of EPCs in the BM and highlight the critical role these cells play in tumor angiogenesis...
  40. ncbi request reprint The multifaceted circulating endothelial cell in cancer: towards marker and target identification
    Francesco Bertolini
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Nat Rev Cancer 6:835-45. 2006
    ....
  41. ncbi request reprint Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
    ..Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies...
  42. ncbi request reprint Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy
    Raquel Munoz
    Sunnybrook and Women s College Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, ONT Canada, M4N 3M5
    Breast 14:466-79. 2005
    ....
  43. doi request reprint Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study
    Julia L Glade Bender
    College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Clin Oncol 26:399-405. 2008
    ..Primary aims included estimating the maximum-tolerated dose (MTD) and determining the dose-limiting toxicities (DLTs), pharmacokinetics, and biologic effects of BV in children with cancer...
  44. pmc Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
    Patrizia Mancuso
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    Blood 108:452-9. 2006
    ..005). Preclinical models indicated that the source of apoptotic CECs was most likely the tumor vasculature. CEC kinetics and viability are very promising as predictors of clinical response in patients undergoing metronomic chemotherapy...
  45. ncbi request reprint Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy
    Raquel Munoz
    Sunnybrook and Women s College Health Sciences Centre S 217, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5
    Cancer Res 66:3386-91. 2006
    ....
  46. ncbi request reprint High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma
    Rena Buckstein
    Medical Oncology, Toronto Sunnybrook Regional Cancer Centre, Sunnybrook and Women s College, Medical Oncology, Princess Margaret Hospital, Ontario, Canada
    Clin Cancer Res 12:5190-8. 2006
    ..Angiogenesis is increased in aggressive histology non-Hodgkin's lymphoma and may be a target with selective cyclooxygenase-2 inhibition and metronomic chemotherapy...
  47. ncbi request reprint Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
    Francesco Bertolini
    Division of Hematology Oncology, Department of Medicine, IFOM Fondazione Italiana per la Ricerca sul Cancro, Institute of Molecular Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy
    Cancer Res 63:4342-6. 2003
    ..Our findings suggest that metronomic low-dose chemotherapy regimens are particularly promising for avoiding CEP mobilization and, hence, to potentially reduce vasculogenesis-dependent mechanisms of tumor growth...
  48. ncbi request reprint On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent
    Yuval Shaked
    J Clin Oncol 24:4040; author reply 4040-1. 2006
  49. pmc Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas
    Robert S Kerbel
    Proc Natl Acad Sci U S A 105:E54; author reply E55. 2008
  50. ncbi request reprint Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients
    David Loven
    Institute of Oncology, Ha Emek Medical Center, Afula 18101, Israel
    Acta Oncol 47:104-9. 2008
    ..Metronomic low-dose chemotherapy regimen was found to have an antiangiogenic effect in tumors. However, its effect on levels of circulating pro-angiogenic and anti-angiogenic factors is not fully explored...
  51. ncbi request reprint Molecular and cellular biomarkers for angiogenesis in clinical oncology
    Francesco Bertolini
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Drug Discov Today 12:806-12. 2007
    ..Here, we discuss the biological and technical facets of the search and validation of new biomarkers for angiogenesis...
  52. doi request reprint Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth
    Fernando Donate
    Attenuon, LLC, San Diego, California 92121, USA
    Clin Cancer Res 14:2137-44. 2008
    ..ATN-161 (Ac-PHSCN-NH(2)) is an integrin-binding peptide that is currently in phase II trials in cancer patients. This peptide has been shown to have antitumor activity in a number of different preclinical models...